Literature DB >> 8195718

Cross-reactivities in memory cytotoxic T lymphocyte recognition of heterologous viruses.

L K Selin1, S R Nahill, R M Welsh.   

Abstract

Analyses of the relationships between different viruses and viral proteins have focused on homologies between linear amino acid sequences, but cross-reactivities at the level of T cell recognition may not be dependent on a conserved linear sequence of several amino acids. The CTL response to Pichinde virus (PV) and vaccinia virus (VV) in C57BL/6 mice previously immunized with lymphocytic choriomeningitis virus (LCMV) included the reactivation of memory cytotoxic T lymphocyte (CTL) specific to LCMV. Limiting dilution assays (LDA) demonstrated that at least part of this reactivation of memory cells in LCMV-immune mice related to cross-reactivity at the clonal level, even though acute infections with these viruses in nonimmune mice elicited CTL responses that did not cross-react in conventional bulk CTL assays. Precursor CTL (pCTL) to LCMV were generated in splenic leukocytes from LCMV-immune mice acutely infected with PV or VV when stimulated in vitro with only the second virus but not with uninfected peritoneal exudate cells (PECs). Cytotoxicity mediated by LCMV-specific CTL clones activated by PV infection was greatly inhibited by anti-CD8 antibody, suggesting that these memory CTL clones recognizing LCMV-infected targets were of low affinity. LCMV-immune splenocytes stimulated in vitro with PV or VV demonstrated a low but significant precursor frequency (p/f) to the heterologous viruses, and splenocytes from PV- or VV-immune mice when stimulated in vitro against LCMV generated a low but significant p/f to LCMV. Short-term CTL clones cross-reactive between LCMV and PV were derived from splenic leukocytes from LCMV-immune mice acutely infected with PV. To distinguish whether the cross-reactivity was directed against a viral peptide or a virus-induced endogenous cellular neoantigen, we demonstrated that a pCTL frequency to PV about 1/4-1/7 that of the frequency to LCMV could be generated from LCMV-immune splenic leukocytes stimulated with the immunodominant LCMV NP peptide. A partially homologous PV peptide generated from the equivalent site to the LCMV NP peptide did not sensitize targets to lysis by either LCMV- or PV-specific CTLs, suggesting that the cross-reactivity in killing was not due to evolutionarily conserved equivalent sequences. Experiments also indicated that prior immunity to one virus could modulate future primary immune responses to a second virus. Elevated pCTL frequencies to PV were seen after acute PV infection of LCMV-immune mice, and elevated pCTL frequencies to LCMV were seen after acute LCMV infection of PV- and VV-immune mice.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8195718      PMCID: PMC2191532          DOI: 10.1084/jem.179.6.1933

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  35 in total

1.  Multiple HLA class I-dependent cytotoxicities constitute the "non-HLA-restricted" response in infectious mononucleosis.

Authors:  G Strang; A B Rickinson
Journal:  Eur J Immunol       Date:  1987-07       Impact factor: 5.532

2.  Generation of large granular T lymphocytes in vivo during viral infection.

Authors:  C A Biron; R J Natuk; R M Welsh
Journal:  J Immunol       Date:  1986-03-15       Impact factor: 5.422

3.  Effect of rabbit anti-asialo GM1 treatment in vivo or with anti-asialo GM1 plus complement in vitro on cytotoxic T cell activities.

Authors:  L Stitz; J Baenziger; H Pircher; H Hengartner; R M Zinkernagel
Journal:  J Immunol       Date:  1986-06-15       Impact factor: 5.422

4.  Exquisite specificity of adoptive immunization in arenavirus-infected mice.

Authors:  K W McIntyre; J F Bukowski; R M Welsh
Journal:  Antiviral Res       Date:  1985-10       Impact factor: 5.970

5.  Recognition of H-2Kb mutant target cells by Moloney virus-specific cytotoxic T lymphocytes from bm13 (H-2Db-mutant) mice. II. Relationship of Kbm3 and Kbm11 in restriction specificities and allodeterminants.

Authors:  M J Stukart; J Boes; C J Melief
Journal:  J Immunol       Date:  1984-07       Impact factor: 5.422

6.  Immunization of mice with vaccinia virus-M2 recombinant induces epitope-specific and cross-reactive Kd-restricted CD8+ cytotoxic T cells.

Authors:  A B Kulkarni; H C Morse; J R Bennink; J W Yewdell; B R Murphy
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

7.  Induction of alloreactive cytotoxic T cells by acute virus infection of mice.

Authors:  H Yang; R M Welsh
Journal:  J Immunol       Date:  1986-02-15       Impact factor: 5.422

8.  The immune response of the mouse to lymphocytic choriomeningitis virus. V. High numbers of cytolytic T lymphocytes are generated in the spleen during acute infection.

Authors:  D Moskophidis; U Assmann-Wischer; M M Simon; F Lehmann-Grube
Journal:  Eur J Immunol       Date:  1987-07       Impact factor: 5.532

9.  Expression of asialo GM1 and other antigens and glycolipids on natural killer cells and spleen leukocytes in virus-infected mice.

Authors:  H Yang; G Yogeeswaran; J F Bukowski; R M Welsh
Journal:  Nat Immun Cell Growth Regul       Date:  1985

10.  Cross-reactive recognition of mouse cells expressing the bm3 and bm11 mutations within H-2Kb by H-2Kb-restricted herpes simplex virus-specific cytotoxic T lymphocytes.

Authors:  S R Jennings
Journal:  J Immunol       Date:  1985-11       Impact factor: 5.422

View more
  112 in total

1.  Cytotoxic T-lymphocyte memory, virus clearance and antigenic heterogeneity.

Authors:  D Wodarz
Journal:  Proc Biol Sci       Date:  2001-02-22       Impact factor: 5.349

Review 2.  Differences in the regulation of CD4 and CD8 T-cell clones during immune responses.

Authors:  P C Beverley; M K Maini
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2000-03-29       Impact factor: 6.237

3.  Role of B cells in maintaining helper T-cell memory.

Authors:  D van Essen; P Dullforce; D Gray
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2000-03-29       Impact factor: 6.237

4.  HIV versus the immune system: another apparent victory for the virus.

Authors:  N L Letvin; B D Walker
Journal:  J Clin Invest       Date:  2001-02       Impact factor: 14.808

Review 5.  Heterologous immunity between viruses.

Authors:  Raymond M Welsh; Jenny W Che; Michael A Brehm; Liisa K Selin
Journal:  Immunol Rev       Date:  2010-05       Impact factor: 12.988

6.  Cross-reactivity of HLA-B*1801-restricted T-lymphocyte clones with target cells expressing variants of the human cytomegalovirus 72kDa-IE1 protein.

Authors:  Virginie Prod'homme; Christelle Retière; Ralitza Valtcheva; Marc Bonneville; Marie-Martine Hallet
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

7.  Bi-specific MHC heterodimers for characterization of cross-reactive T cells.

Authors:  Zu T Shen; Michael A Brehm; Keith A Daniels; Alexander B Sigalov; Liisa K Selin; Raymond M Welsh; Lawrence J Stern
Journal:  J Biol Chem       Date:  2010-08-20       Impact factor: 5.157

8.  Longitudinal analysis of the T-cell receptor (TCR)-VA and -VB repertoire in CD8+ T cells from individuals immunized with recombinant hepatitis B surface antigen.

Authors:  H Höhn; C Neukirch; K Freitag; A Necker; W Hitzler; B Seliger; M J Maeurer
Journal:  Clin Exp Immunol       Date:  2002-08       Impact factor: 4.330

9.  PC61 (anti-CD25) treatment inhibits influenza A virus-expanded regulatory T cells and severe lung pathology during a subsequent heterologous lymphocytic choriomeningitis virus infection.

Authors:  Anke R M Kraft; Myriam F Wlodarczyk; Laurie L Kenney; Liisa K Selin
Journal:  J Virol       Date:  2013-09-18       Impact factor: 5.103

10.  Cross-reactivity of T lymphocytes recognizing a human cytotoxic T-lymphocyte epitope within BK and JC virus VP1 polypeptides.

Authors:  Ludmila Krymskaya; Madeva C Sharma; Joy Martinez; Wahajul Haq; Eric C Huang; Ajit P Limaye; Don J Diamond; Simon F Lacey
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.